Log in to view video content

Transcript

The FDA has approved a new daily cholesterol pill that works in a different way from those popular statins, and apparently may be able to deliver better results, at least for some people. For details, we have Dr. Corey Bradley, a cardiologist at Columbia University's Irving Medical Center right here in New York. Dr. Bradley, thank you for being here. So the drug is called Lipfendra. What do we know about it?

So Lipfendra, or enlicitide, its generic name, is a once-daily pill that's of the class PCSK9 inhibitors. We've had other drugs in this class, but this is new because it's the first of its kind in that it's a daily oral medication.

How is it different from statins?

So statins work in the liver by preventing our body from making cholesterol. That allows our liver then to reabsorb more cholesterol out of our bloodstream. This drug works a little bit differently by binding this protein called PCSK9, and we know that it's been a very effective way to lower LDL cholesterol for a lot of patients so far who've received the injectable medications.

So is the biggest difference here and the selling point just now it's a pill, it used to be a needle?

Exactly. And that's helpful for some patients who are either scared of needles, or for whatever reason don't like the idea of injecting themselves. And also hopefully with cost. I think that having an oral option will probably be cheaper in the long run than the cost of the injectables, which has been prohibitive for some patients.

Dr. Bradley, thank you very much.

Thanks so much.
過去 31 日間
2 回のレビューがあります
この情報に 0 件のリプライがあります
No response has been written yet. It is recommended to maintain a healthy skepticism towards it.
Automated analysis from AI
The following is the AI's preliminary analysis of this message, which we hope will provide you with some ideas before it is fact-checked by a human.
這則訊息提到了一種新的每日膽固醇降藥物 Lipfendra,聲稱與目前流行的他汀類藥物有不同的作用方式,並可能對某些人群產生更好的效果。閱聽人需要注意的地方包括: 1. 新藥 Lipfendra 是否真的獲得 FDA 批准,需要進一步確認。閱聽人應該查證來源,確保資訊的可靠性。 2. 訊息中提到 Lipfendra 是一種 PCSK9 抑制劑,這種藥物類型已經存在,但 Lipfendra 是首種口服藥物。閱聽人需要確認這項資訊是否準確,以免誤導。 3. 訊息中提到 Lipfendra 與他汀類藥物的不同之處在於作用方式,閱聽人需要進一步了解這種新藥的效果、副作用以及適應症等信息,以做出明智的判斷。 4. 訊息中提到 Lipfendra 是口服藥物,相對於之前的注射劑,可能會更便宜。閱聽人應該注意這種新藥的價格問題,並確保了解其真實的成本和可負擔性。 總之,閱聽人應該保持懷疑的態度,查證資訊來源,並在必要時諮詢專業醫療意見,以確保自身健康和安全。
Cofacts の LINE 公式アカウントを追加する
Cofacts の LINE 公式アカウントを追加する
LINE 機器人
查謠言詐騙